Matt Miksic
Stock Analyst at Barclays
(1.84)
# 1195
Out of 5,332 analysts
266
Total ratings
57.14%
Success rate
7.00%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
OBIO Orchestra BioMed Hld... | Maintains: Overweight | 16 12 | 2.47 | 385.83% | 2 | May 5, 2025 | |
DXCM DexCom | Maintains: Equal-Weight | 90 93 | 82.15 | 13.21% | 6 | May 5, 2025 | |
PODD Insulet | Maintains: Equal-Weight | 234 266 | 259.89 | 2.35% | 8 | Apr 30, 2025 | |
INMD InMode | Maintains: Overweight | 29 24 | 14.27 | 68.19% | 13 | Apr 30, 2025 | |
BSX Boston Scientific | Maintains: Overweight | 118 125 | 104.25 | 19.9% | 14 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 684 635 | 530.8 | 19.63% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 166 165 | 155.25 | 6.28% | 12 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 158 159 | 132.22 | 20.25% | 26 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 39 41 | 30.31 | 35.27% | 17 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 58 56 | 36.04 | 55.38% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 60 53 | 22 | 140.91% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 103 | 71.2 | 44.66% | 14 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 88 90 | 75 | 20% | 23 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 118 112 | 90.76 | 23.4% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 418 443 | 378.43 | 17.06% | 21 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 21 | 11.96 | 75.59% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 4.05 | 443.21% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 105 109 | 82.65 | 31.88% | 15 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 16 | 8.88 | 80.18% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 17 18 | 11.24 | 60.14% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 56 58 | n/a | n/a | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 15 | n/a | n/a | 1 | Dec 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 96 | 96.55 | -0.57% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 100 | 67.23 | 48.74% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 722 418 | 177.28 | 135.79% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 31 28 | 12.93 | 116.55% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 68 67 | 13.64 | 391.2% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 11 4 | n/a | n/a | 4 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 480 | 8.34 | 5655.4% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 84 87 | 13.2 | 559.09% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 24 25 | 5.32 | 369.92% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 200 160 | n/a | n/a | 2 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 26 24 | n/a | n/a | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sell | 9 | 6.62 | 35.95% | 1 | Dec 12, 2016 |